Novel Small-Molecule AMP-Activated Protein Kinase Allosteric Activator with Beneficial Effects in db/db Mice
Figure 6
Chronic effects of ZLN024 in db/db mice.
Eight-week-old male db/db mice were gavaged with vehicle (0.5% methylcellulose), ZLN024 (15 mg/kg/day) or metformin (250 mg/kg−/day) (n = 6–8). (A) Blood glucose levels after an intra-peritoneal glucose load (1.5 g/kg) performed after 4 weeks of treatment. The AUC were used as an indicator of glucose clearance. White circles, vehicle; black circles, ZLN024; white squares, metformin. (B) Amount of liver tissue in proportion to body weight (wt/wt) after 5 weeks of treatment. (C) Liver triacylglycerol level after 5 weeks of treatment. (D) Liver total cholesterol level after 5 weeks of treatment. (E) Relative anabolic gene expression levels in the liver. (F) Relative catabolic gene expression levels in the liver. (G) Relative gene expression levels in abdominal muscle. (H) AMPK and ACC phosphorylation levels in the abdominal muscle. (I) AMPK and ACC phosphorylation levels in the liver. *, P<0.05, **, P<0.01 compared with vehicle.